ProQR Therapeutics (NASDAQ:PRQR) Stock Passes Below Fifty Day Moving Average – Time to Sell?

ProQR Therapeutics N.V. (NASDAQ:PRQR)’s stock price crossed below its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $2.31 and traded as low as $2.02. ProQR Therapeutics shares last traded at $2.04, with a volume of 684,480 shares.

Analyst Ratings Changes

Several brokerages recently commented on PRQR. Zacks Research upgraded shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Chardan Capital reaffirmed a “buy” rating and set a $4.00 price objective on shares of ProQR Therapeutics in a report on Tuesday, November 4th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of ProQR Therapeutics in a research report on Wednesday, October 8th. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $7.14.

ProQR Therapeutics Stock Performance

The company has a market capitalization of $214.63 million, a PE ratio of -4.34 and a beta of 0.18. The company’s 50-day simple moving average is $2.31 and its 200-day simple moving average is $2.24.

ProQR Therapeutics (NASDAQ:PRQR) last announced its earnings results on Thursday, November 6th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). ProQR Therapeutics had a negative net margin of 273.20% and a negative return on equity of 58.70%. The business had revenue of $3.38 million during the quarter, compared to analysts’ expectations of $7.05 million. Analysts expect that ProQR Therapeutics N.V. will post -0.31 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of PRQR. Osaic Holdings Inc. increased its holdings in shares of ProQR Therapeutics by 59.6% in the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 4,500 shares during the period. Raymond James Financial Inc. lifted its holdings in shares of ProQR Therapeutics by 15.2% during the third quarter. Raymond James Financial Inc. now owns 110,270 shares of the biopharmaceutical company’s stock worth $235,000 after purchasing an additional 14,549 shares during the period. OneDigital Investment Advisors LLC grew its position in ProQR Therapeutics by 23.1% in the 3rd quarter. OneDigital Investment Advisors LLC now owns 80,000 shares of the biopharmaceutical company’s stock valued at $170,000 after buying an additional 15,000 shares during the last quarter. BNP Paribas Financial Markets increased its stake in ProQR Therapeutics by 14.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 139,594 shares of the biopharmaceutical company’s stock valued at $297,000 after buying an additional 18,100 shares during the period. Finally, Sio Capital Management LLC increased its stake in ProQR Therapeutics by 1.0% in the 2nd quarter. Sio Capital Management LLC now owns 2,075,139 shares of the biopharmaceutical company’s stock valued at $4,233,000 after buying an additional 20,546 shares during the period. 32.65% of the stock is currently owned by hedge funds and other institutional investors.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.